Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04836793
Status:
UNKNOWN
Last Update Posted:
2021-06-08
First Post:
2021-04-06
Brief Title:
COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Study of Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination to Predict Immune Responses in Cancer Patients
Status:
UNKNOWN
Status Verified Date:
2021-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CACOV-VAC
Brief Summary:
T-cell adaptive immunity is known to be required to sustain a long term immunoglobulin production and a long term memory against several infections Previous results suggest a lack in the generation of T-cell responses against CoV-N M and S proteins among cancer patients exposed to SARS-CoV-2 virus highlighting that cancer patients failed to mount a protective T-cell immunity Given this context our hypothesis is that COVID-19 vaccine candidates are not immunogenic in some cancer patients Thus the monitoring of CD4 and CD8 T-cell responses before and after vaccination might provide information related to the correlation between induction of CD4 T-cells including helper follicular T-cells by the vaccine and long-term IgG production serological index Additionally the failure of COVID-19 vaccines in some patients should be monitor carefully in order to provide specific recommendations to avoid COVID-19 infections The main objective is to assess humoral immune responses following COVID-19 vaccination in a population of cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None